<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="45679">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02511587</url>
  </required_header>
  <id_info>
    <org_study_id>RV_FSME_1.2</org_study_id>
    <nct_id>NCT02511587</nct_id>
  </id_info>
  <brief_title>Comparison of Vaccination Routes: Subcutaneous Versus Intramuscular Application of FSME-Immun®</brief_title>
  <official_title>Comparison of Vaccination Routes: Subcutaneous Versus Intramuscular Application of FSME-Immun®</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      FSME-Immun® is registered for application into the muscle. This study investigates if
      application under the skin leads to a comparable immune response.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tick-borne encephalitis (TBE) vaccine (FSME-Immun®) is registered for intra-muscular
      application. Due to medical reasons (e.g. anticoagulant therapy, adipositas) intra-muscular
      application is not always possible. The aim of this clinical trial is to investigate whether
      a comparably good immunogenicity can be achieved via the subcutaneous vaccination route.
      Thus humoral and cellular immune responses after intramuscular and subcutaneous TBE
      vaccination in healthy volunteers will be compared.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Humoral immunity to TBE vaccine</measure>
    <time_frame>1 month</time_frame>
    <description>GMT of TBE Neutralisation test titers one month after booster vaccination</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cellular immune responses - cytokines</measure>
    <time_frame>before (day 0) and 1week after booster vaccination</time_frame>
    <description>cytokine production of antigen-specifically restimulated PMBC is evaluated (Interleukin 2, Interleukin 10, Interferon gamma)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TBE titer profile</measure>
    <time_frame>before (day 0) and 1week, 1 month, 6 months after booster vaccination</time_frame>
    <description>TBE specific neutralizing Ab titer profiles (GMT)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">116</enrollment>
  <condition>Vaccine Efficacy</condition>
  <arm_group>
    <arm_group_label>intra muscular application</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intra muscular application of FSME-Immune vaccination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>subcutaneous application</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subcutaneous application of FSME-Immune vaccination</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>FSME-Immune vaccination</intervention_name>
    <description>booster vaccination with FSME-Immune</description>
    <arm_group_label>intra muscular application</arm_group_label>
    <arm_group_label>subcutaneous application</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  completed primary TBE immunization + at least one booster immunization

          -  adults of both sexes between 18 and 60 years of age

          -  willingness to sign written informed consent form

        Exclusion Criteria:

          -  age &lt; 18 and &gt; 60 years

          -  prior TBE infection

          -  pregnancy and breast feeding

          -  acute infection on day of inclusion (day 0), (body temperature &gt; 37,9°C)

          -  concomitant medications: systemic cortisone therapy, chemotherapy, immunosuppressive
             therapy 4 weeks prior to or during study

          -  administration of other vaccines 4 weeks before/after day 0

          -  planned surgery within 2 weeks before/after TBE booster vaccination

          -  specific immunotherapy (Hypo-/Desensibilisation) 14 days before/after vaccination

          -  any contraindication to administration of FSME-Immun® vaccine according to
             manufacturer's instructions

          -  history of malignant disease within the last 5 years

          -  autoimmune diseases

          -  drug addictions

          -  plasma donors

          -  receipt of blood transfusions or immuno globulins within 3 month before study entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ursula Wiedermann, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University Vienna, ISPTM</affiliation>
  </overall_official>
  <verification_date>July 2015</verification_date>
  <lastchanged_date>July 29, 2015</lastchanged_date>
  <firstreceived_date>July 23, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Univ. Prof. Dr. Ursula Wiedermann</investigator_full_name>
    <investigator_title>Univ.-Prof. Dr. Ursula Wiedermann</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
